去泛素化酶USP38通过稳定RBM14促进胃癌进展的机制研究
|
|
陈赟琪, 那迪娜·帕尔哈提, 张鹏善, 黄陈
|
Deubiquitinase USP38 promotes gastric cancer progression by stabilizing RBM14
|
|
Chen Yunqi, Paerhati Nadina, Zhang Pengshan, Huang Chen
|
|
表1 USP38 表达水平与胃癌临床病理特征相关性分析
|
Tab 1 Association between USP38 expression and clinicopathological characteristics of gastric cancer
|
|
| Variable | Overall (n =458) | Low (n =229) | High (n =229) | P value |
|---|
| Age/year | 67.5 (58.0, 74.0) | 67.0 (58.0, 72.0) | 68.0 (60.0, 75.0) | 0.051 | | Gender/n(%) | | | | 0.005 | | Female | 167 (36.5) | 69 (30.1) | 98 (42.8) | | | Male | 291 (63.5) | 160 (69.9) | 131 (57.2) | | | Histologic grade/n(%) | | | | 0.600 | | G1 | 13 (2.9) | 6 (2.7) | 7 (3.1) | | | G2 | 168 (37.8) | 88 (40.0) | 80 (35.6) | | | G3 | 264 (59.3) | 126 (57.3) | 138 (61.3) | | | Pathologic stage/n(%) | | | | 0.017 | | Stage Ⅰ | 68 (16.2) | 34 (15.7) | 34 (16.7) | | | Stage Ⅱ | 142 (33.8) | 88 (40.7) | 54 (26.5) | | | Stage Ⅲ | 165 (39.3) | 73 (33.8) | 92 (45.1) | | | Stage Ⅳ | 45 (10.7) | 21 (9.7) | 24 (11.8) | | | T stage/n(%) | | | | 0.066 | | T1 | 25 (5.7) | 12 (5.2) | 13 (6.1) | | | T2 | 104 (23.5) | 49 (21.4) | 55 (25.8) | | | T3 | 201 (45.5) | 118 (51.5) | 83 (39.0) | | | T4 | 112 (25.3) | 50 (21.8) | 62 (29.1) | | | N stage/n(%) | | | | 0.200 | | N0 | 141 (32.9) | 81 (37.0) | 60 (28.6) | | | N1 | 120 (28.0) | 61 (27.9) | 59 (28.1) | | | N2 | 88 (20.5) | 38 (17.4) | 50 (23.8) | | | N3 | 80 (18.6) | 39 (17.8) | 41 (19.5) | | | M stage/n(%) | | | | 0.800 | | M0 | 402 (93.3) | 200 (93.0) | 202 (93.5) | | | M1 | 29 (6.7) | 15 (7.0) | 14 (6.5) | |
|
|
|